Jump to content

Talk:Incyte

Page contents not supported in other languages.
Add topic
From Wikipedia, the free encyclopedia
Latest comment: 2 months ago by INCY Erik in topic Updated Pharmaceuticals section

[Untitled]

[edit]
Latest comment: 5 years ago2 comments1 person in discussion

Basic financial information is out of date by several years, and can be verified easily with more current information. I am updating to the 2020 numbers https://www.nasdaq.com/market-activity/stocks/incy/financials DonInUtah (talk) 01:23, 27 July 2021 (UTC)Reply

Updated some of the company information and list of current drugs per verified information and SEC filings. I will look through other sections of the edit request to see that they are independently verified, meet wikipedia guidelines, and will include or exclude accordingly. DonInUtah (talk) 23:56, 26 July 2021 (UTC)Reply

Edit Request

[edit]

My name is Catalina Loveman and work for Incyte, a biotechnology company. In my role as Executive Director of Public Affairs, I manage all corporate communications efforts for the company. To be transparent, I will list my COIs, brands and any articles I work on below.

Company – Incyte

I am aware of Wikipedia's policies and guidelines, including those on WP:COI, WP:RS, WP:V and WP:NPOV, and I will abide by them. My edit suggestions will be restricted to Talk pages, and I will not engage in directly editing any articles related to the company/brands which I present, aside from correcting/reverting blatant misinformation or obvious vandalism.

On any pages where I may suggest changes, I will be sure to disclose relevant relationships in the interest of transparency on the Talk pages and state that I am not NPOV.

If you have any questions about my editing activities, please leave me a message on my User Talk page.

I would like to propose the following edits to the Incyte infobox:

  • Update financials to be current as of 2020: Net income (decrease) $US 149.85 million (2020); Total assets $US 3.56 billion (2020); Total equity $US 2.61 billion (2020) [1]
  • In “Number of employees,” reflect publicly-available figure: 1,600+[2]


I would like to propose the following edits to the introduction for accuracy:

  • Add a second sentence to reflect number of employees: It employs more than 1,600 employees. [3]
  • Update the following paragraphs in this section to more accurately describe Incyte medicines (i.e., the company has more than one drug): It receives royalties from three products – Jakavi® (ruxolitinib) ex-U.S., which is licensed to Novartis, and Olumiant® (baricitinib) and Tabrecta® (capmatinib) globally, which are licensed to Eli Lilly and Novartis, respectively. [4][5] The company is advancing a portfolio of medicines across Oncology and Inflammation & AutoImmunity. [6]


Finally, I would like to propose the addition of an external link: Incyte Corporate Website (www.incyte.com).

Please let me know if you have any feedback to these proposed changes.

References

  1. ↑ "Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Provides Updates on Key Clinical Programs". Incyte.com. Retrieved 2021-06-09.
  2. ↑ "Viewpoint: Delaware-born Incyte makes a global impact during crisis". Delaware Business Times. Retrieved 2021-06-09.
  3. ↑ "Viewpoint: Delaware-born Incyte makes a global impact during crisis". Delaware Business Times. Retrieved 2021-06-09.
  4. ↑ "Form 8-K, Incyte Corporation" (PDF). sec.gov. Retrieved 2021-06-09.
  5. ↑ "Our Leadership". Incyte.com. Retrieved 2021-06-09.
  6. ↑ "Our Leadership". Incyte.com. Retrieved 2021-06-09.

Details about founding?

[edit]
Latest comment: 3 years ago1 comment1 person in discussion

There seems to be something odd going on with the dates of founding. "The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware." First off, from the reference it looks like the merger actually officially took effect in 2003, it's just that Incyte lists 2002 as their founding date (https://www.incyte.com/who-we-are/biopharmaceutical-research). And it's also rather suspicious that they happened to have the same name as another company they're merging with.

To me it sure sounds like "Genomics" was a "shell" company specifically set up to take over "Pharmaceuticals" (and probably restructure their corporate structure.) - That is, it isn't really a "merger" of two independent companies, but rather it's a corporate restructuring which was framed as a merger for legalistic purposes. I'm not sure if Wikipedia readers are best served by the current phrasing, though since I'm lacking a bunch of the details and Incyte officially claim 2002 as their founding date I'm not sure how best to rephrase things. -- 129.59.122.107 (talk) 18:36, 13 February 2023 (UTC)Reply

Founder

[edit]
Latest comment: 1 year ago1 comment1 person in discussion

Why is the founder listed as George Washington in 1776? 100.19.9.122 (talk) 05:28, 29 September 2025 (UTC)Reply

Updated "History" section

[edit]
Latest comment: 2 months ago5 comments2 people in discussion

I'm Erik and I work at Incyte. I'm excited to collaborate with you all! Due to my conflict of interest, I am here with a request.

I'd like to request the wholesale replacement of the current History section on this article, with my proposed version. Half the citations in the current section are press releases or non-reliable sources, and the section itself doesn't really tell the story of Incyte's company history; it bounces from 2025 to 2015 to 2020 to 2021. The current section only really highlights two milestones in Incyte's history, and lacks a ton of context that is included in reliable sourcing. This proposed version tells that history more completely, while also improving the sourcing throughout.

Replace

In June 2025, Incyte named Bill Meury president, CEO, and a member of the board of directors. He replaced Hervé Hoppenot, who retired after 11 years of service.[1]
In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[2]
In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.[3] On March 3, 2020, the agreement received antitrust clearance and thus became effective.[4]
Incyte established a European headquarters in Morges, Switzerland, in 2021.[5]

with this proposed content:

Incyte Corporation was founded by Roy A. Whitfield on April 8, 1991, in Palo Alto, California, as a genomics company. It became a public company in 1993.[1][2] Subsequently, scientists and chemists were recruited from DuPont to work for Incyte.[1][2] Incyte moved its headquarters to Delaware, and acquired Maxia Pharmaceuticals in 2003.[3][4][5]
In November 2013, Incyte announced its relocation to new headquarters in Wilmington, Delaware, completing the move by the end of 2014.[6][7][8] Hervé Hoppenot became CEO in January 2014.[7]
In 2017, the company became part of the S&P 500 Index, which tracks the 500 most widely held U.S. stocks.[9]
In 2015, Incyte established its European headquarters in Geneva, Switzerland, and later moved this headquarters in 2021.[10][11][12] The company expanded its Delaware headquarters, including the addition of a major research and development facility, in 2022.[3] That same year, Incyte acquired Villaris Therapeutics, and Escient Pharmaceuticals in 2024.[13][14]
For 2025, the company reported $5.141 billion in revenue, $6.957 billion in assets and $1.286 billion in net income.[15][16] Incyte is publicly traded on the NASDAQ under the symbol INCY.[2] Incyte now operates out of North America, Asia, and Europe.[17] Bill Meury became CEO in 2025.[18] Meury replaced Hoppenot, who retired after 11 years in the position.[7][18]

References

  1. 1 2 Milford, Maureen (November 21, 2014). "Incyte takes over reimagined Wanamaker building". Delaware Online. Retrieved December 12, 2025.
  2. 1 2 3 "Incyte". Forbes Magazine. 2025. Retrieved December 17, 2025.
  3. 1 2 Owens, Jacob (April 4, 2022). "Incyte opens new R&D lab in Wilmington". Delaware Business Times. Retrieved December 12, 2025.
  4. ↑ Baker, Karl (August 5, 2020). "Incyte progresses on COVID-19 treatment. Other big Delaware companies slog through tough economy". Delaware Online. Retrieved December 12, 2025.
  5. ↑ UNITED STATES SECURITIES AND EXCHANGE COMMISSION (2002). "QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934". SECURITIES AND EXCHANGE COMMISSION. Retrieved December 17, 2025.
  6. ↑ Malcolm, Wade (November 17, 2013). "Incyte to lease former Wanamaker building near Wilmington". Delaware Online. Retrieved December 12, 2025.
  7. 1 2 3 Anne Natoli, Cori (January 16, 2014). "Rising Incyte Corp. welcomes new CEO". Delaware Online. Retrieved December 12, 2025.
  8. ↑ Goss, Scott (March 3, 2015). "Incyte wins Delaware Bio company of the year honor, again". Delaware Online. Retrieved December 12, 2025.
  9. ↑ Mordock, Jeff (February 28, 2017). "Incyte joins prestigious Standard & Poor's 500 index". Delaware Online. Retrieved December 12, 2025.
  10. ↑ "Incyte to establish European headquarters in Geneva". 15 July 2020. Retrieved 12 September 2021. New facility to serve as European base for Incyte's drug development operations, and provides efficient access to key clinical trial experts and institutions.
  11. ↑ "Prof. Jocelyne Bloch and Prof. Grégoire Courtine receive the BioAlps Academia Award, and Incyte the BioAlps Industry Award". Bio Alps. November 25, 2022. Retrieved May 4, 2026.
  12. ↑ Wilson, Xerxes (July 31, 2015). "Incyte considering 400 job expansion near Wilmington". Delaware Online. Retrieved May 4, 2026.
  13. ↑ George, John (October 3, 2022). "Incyte to acquire North Carolina drug developer in deal valued at up to $1.36 billion". Philadelphia Business Journal. Retrieved December 17, 2025.
  14. ↑ Tabeling, Katie (June 3, 2024). "Incyte closes $750M deal for Escient Pharmaceuticals". Delaware Business Times. Retrieved December 17, 2025.
  15. ↑ "Incyte Corp. 2025 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 10, 2026.
  16. ↑ Incyte (February 10, 2026). "Incyte Reports Fourth Quarter and Full Year 2025 Financial Results". Incyte. Archived from the original on March 31, 2026. Retrieved March 31, 2026.
  17. ↑ Tabeling, Katie (October 23, 2024). "Incyte celebrated at du Pont Freedom Award reception". Delaware Business Times. Archived from the original on May 22, 2025. Retrieved December 17, 2025.
  18. 1 2 Tabeling, Katie (June 30, 2025). "Meury named Incyte CEO as Hoppenot departs". Delaware Business Times. Archived from the original on March 31, 2026. Retrieved March 31, 2026.

Let me know if anyone has questions here, and thanks INCY Erik (talk) 15:43, 8 June 2026 (UTC)Reply

Dear Erik, I have a couple suggestions
You suggest to add "The company expanded its Delaware headquarters, including the addition of a major research and development facility, in 2022." I think it might be better to simply state research and development facility and omit major.
Also, you state "The company expanded its Delaware headquarters, including the addition of a major research and development facility, in 2022. That same year, Incyte acquired Villaris Therapeutics, and Escient Pharmaceuticals in 2024." The inclusion of "that same year" is a bit confusing. Maybe exclude it?
Besides that, your article looks pretty good! Feel free to tag me once you address the issues, or alternatively, let me know if you disagree. Thanks! - Otherwise (Talk?) 16:10, 27 July 2026 (UTC)Reply
Thank you for your feedback, Otherwise! I agree with your points, but just to be specific:
  • Agreed, so it would read: "The company expanded its Delaware headquarters, including the addition of a research and development facility, in 2022."? If so, let's do it.
  • Villaris was acquired in 2022, which is why I said "That same year". However, if that's too confusing, maybe we go with this: "Incyte acquired Villaris Therapeutics in 2022, and Escient Pharmaceuticals in 2024."
Let me know what you think, and thanks INCY Erik (talk) 16:21, 29 July 2026 (UTC)Reply
Go ahead: I have reviewed these proposed changes and suggest that you go ahead and make the proposed changes to the page. Please do not make any other changes besides the ones that you have explicitly outlined here. Thanks! - Otherwise (Antibacklog Aktion!) (talk?) 16:55, 29 July 2026 (UTC)Reply
Thank you Otherwise! Doing so now. Let me know if it looks alright. INCY Erik (talk) 12:40, 31 July 2026 (UTC)Reply

Updated Pharmaceuticals section

[edit]
Latest comment: 2 months ago1 comment1 person in discussion

I'm Erik and I work at Incyte. I'm back with another COI request. I'm mentioning you here, Otherwise, in case you're interested in taking a look again.

I'd like to request the replacement of the current Pharmaceuticals section, with a more detailed version that expands it with available sourcing.

The current section references websites like Business Wire and Incyte's own website, and the last two paragraphs contain outdated information on drug development. My proposed version more clearly shows the main pharmaceuticals and research Incyte is known for, removes unreliable sourcing (including both primary sources and nonjournalistic sites), and increases readability with clear subsections.

  • I propose replacing the current live version:
Pharmaceuticals

Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib).[1][2] In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.[3]

As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[4][5] It gained EU approval in February 2017.[6] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[7][8] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.[9][10]

As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).[11][12]

References

  1. ↑ "incy_Current folio_10K". www.sec.gov. Retrieved 2021-07-26.
  2. ↑ "portfolio.pdf" (PDF). www.incyte.com. Retrieved 2022-12-18.
  3. ↑ "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. 29 April 2013. Retrieved 2015-12-29.
  4. ↑ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Retrieved 2 Mar 2015.
  5. ↑ "Baricitinib" (PDF). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
  6. ↑ "Olumiant: Authorisation details". European Medicines Agency. 16 March 2017.
  7. ↑ Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
  8. ↑ Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
  9. ↑ Research, Center for Drug Evaluation and (2019-02-09). "Drug Trials Snapshots: OLUMIANT". FDA. Archived from the original on September 28, 2019.
  10. ↑ "Drug Approval Package: Olumiant (baricitinib)". www.accessdata.fda.gov. Retrieved 2021-07-27.
  11. ↑ Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European Journal of Cancer. 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.
  12. ↑ Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.
  • And adding my proposed version:
Research and products
Pharmaceuticals

Incyte has a portfolio of products and research across Oncology, Hematology, Inflammation and Autoimmunity, and including dermatology.[1] Their United States Food and Drug Administration-approved list of medications include Jakafi, Opzelura, Pemazyre, Monjuvi, Iclusig, Niktimvo, Zynyz, and Olumiant.[2][3][4][5]

Jakafi

Incyte formed a licensing agreement with Novartis in 2009, granting them the rights to develop and sell Jakafi outside the United States.[6]

In 2011, Incyte received its first U.S. Food and Drug Administration approval for Jakafi, the first drug approved for myelofibrosis, a rare blood cancer.[7] Jakafi was subsequently approved for polycythemia vera and acute and chronic graft-versus-host disease.[8][9]

Opzelura

Incyte developed Opzelura, which was the first topical Janus kinase inhibitor approved for atopic dermatitis and vitiligo.[10][11][12]

Monjuvi

In February 2024, Incyte paid $25 million to acquire full global rights to Monjuvi, an FDA-approved anti-CD19 antibody, from MorphoSys. Both companies had previously shared U.S. development and commercialization costs, with Incyte holding rights elsewhere, after a $750 million upfront payment in 2020.[13] The FDA approved Monjuvi in combination with lenalidomide in 2020, for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[14]

Incyte conducted a phase three trial of Monjuvi, where 57% of follicular lymphoma patients experienced a reduction in the risk of disease progression, relapse or death when treated with Monjuvi in combination with lenalidomide and rituximab. The FDA approved Monjuvi in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma as of 2025.[14] Monjuvi generated $41.9 million in U.S. sales in 2025.[15]

Zynyz

Zynyz has FDA approval as a first-line treatment for advanced anal cancer, specifically metastatic squamous cell carcinoma of the anal canal (SCAC), to be used alone or with platinum-based chemotherapy. Clinical trials showed Zynyz combined with chemotherapy reduced the risk of disease progression by 37%, though additional survival studies are ongoing. Zynyz sales are a small portion of Incyte’s overall revenue as of 2025.[16]

References

  1. ↑ Owens, Jacob (June 9, 2023). "Incyte sees growing opportunity in dermatology". Delaware Business Times. Archived from the original on May 23, 2025. Retrieved December 17, 2025.
  2. ↑ Tabeling, Katie (October 23, 2024). "Incyte celebrated at du Pont Freedom Award reception". Delaware Business Times. Archived from the original on May 22, 2025. Retrieved December 17, 2025.
  3. ↑ "Incyte Corp". CNBC. December 11, 2025. Retrieved December 12, 2025.
  4. ↑ Mordock, Jeff (September 8, 2015). "Incyte spending $80 million for headquarters land". Delaware Online. Retrieved December 17, 2025.
  5. ↑ Jensen, Kristin (June 14, 2022). "FDA approves Lilly, Incyte drug for alopecia, but includes safety warning". BioPharmaDive. Retrieved December 18, 2025.
  6. ↑ Staff (November 25, 2009). "Novartis strikes licensing deal with Incyte". Reuters. Retrieved December 12, 2025.
  7. ↑ Baker, Karl (November 16, 2011). "US approves Incyte's rare bone marrow disease drug". Reuters. Retrieved December 12, 2025.
  8. ↑ Mordock, Jeff (November 4, 2015). "Incyte revenue projections for cancer drug Jakafi rise". Delaware Online. Retrieved December 12, 2025.
  9. ↑ Staff (October 29, 2024). "Incyte raises 2024 sales forecast for top-selling drug Jakafi". Reuters. Retrieved December 12, 2025.
  10. ↑ Choudhury, Kamal (February 10, 2025). "Incyte forecasts downbeat annual sales of skin disease drug, shares fall". Reuters. Retrieved December 12, 2025.
  11. ↑ Staff (May 17, 2021). "Incyte's vitiligo treatment meets main goal in late-stage trial". Reuters. Retrieved December 12, 2025.
  12. ↑ Satija, Bhanvi; Maddipatla, Manojna (September 22, 2021). "FDA approves Incyte's eczema cream with boxed warnings". Reuters. Retrieved December 12, 2025.
  13. ↑ Becker, Zoey (February 6, 2024). "Incyte picks up full Monjuvi rights from partner MorphoSys for $25M". Fierce Pharma. Retrieved December 17, 2025.
  14. 1 2 U.S. Food and Drug Administration. "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). Food and Drug Administration. Archived from the original (PDF) on March 31, 2026. Retrieved March 31, 2026.
  15. ↑ Incyte (February 10, 2026). "Incyte Reports Fourth Quarter and Full Year 2025 Financial Results". Incyte. Archived from the original on March 31, 2026. Retrieved March 31, 2026.
  16. ↑ Tabeling, Katie (May 16, 2025). "Incyte's Zynyz receives FDA approval for advanced anal cancer treatment". Delaware Business Times. Retrieved January 29, 2026.

If any more clarification is needed, I would be happy to have a chat. Let me know if anyone has questions here, and thanks INCY Erik (talk) 15:54, 5 August 2026 (UTC)Reply

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Incyte&oldid=1367853181"